The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1537
January 1, 2018
View Complete Issue         Table of Contents 2019 
Triptorelin (Triptodur) for Central Precocious Puberty
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Triptorelin (Triptodur) for Central Precocious Puberty
January 1, 2018 (Issue: 1537)
The FDA has approved an extended-release intramuscular suspension formulation of the gonadotropin-releasing hormone (GnRH) agonist triptorelin (Triptodur – Arbor/Debiopharm) for twice-yearly treatment of central precocious puberty (CPP) in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Triptorelin (Triptodur) for Central Precocious Puberty
Article code: 1537d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.